Sugi Predict

Sugi Predict / Compounds / SCHEMBL4452280

SCHEMBL4452280

SCHEMBL4452280

CC(C)(C)c1ccc(CC(=O)NCc2ccc3c(c2)CN(C2CCC(=O)NC2=O)C3=O)cc1

nearest known ligand 0.66

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 12/20 0.66
▸ GSPT1 P15170 4/20 0.66
▸ DDB1 Q16531 2/20 0.66
▸ CYP2C19 P33261 1/20 0.66
▸ KCNH2 Q12809 1/20 0.66
▸ IKZF3 Q9UKT9 1/20 0.61
▸ WIZ O95785 1/20 0.55
▸ IKZF1 Q13422 1/20 0.53
▸ CSNK1A1 P48729 2/20 0.52
▸ IKZF2 Q9UKS7 6/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29421149 1.00 CRBN (0.66) CRBNGSPT1DDB1CYP2C19KCNH2
SCHEMBL1413399 0.91 CRBN (0.71) CRBNGSPT1DDB1CYP2C19KCNH2
SCHEMBL1413448 0.90 CRBN (0.67) CRBNGSPT1DDB1CYP2C19KCNH2
SCHEMBL1403628 0.90 CRBN (0.66) CRBNGSPT1DDB1CYP2C19KCNH2
SCHEMBL22929084 0.90 CRBN (0.65) CRBNGSPT1DDB1CYP2C19KCNH2
SCHEMBL22929057 0.90 CRBN (0.65) CRBNGSPT1DDB1CYP2C19KCNH2
SCHEMBL26148387 0.89 CRBN (0.63) CRBNGSPT1DDB1CYP2C19KCNH2
SCHEMBL1403552 0.89 CRBN (0.74) CRBNGSPT1DDB1CYP2C19KCNH2
SCHEMBL16381535 0.89 CRBN (0.62) CRBNGSPT1DDB1CYP2C19KCNH2
SCHEMBL1403675 0.89 CRBN (0.62) CRBNGSPT1DDB1CYP2C19KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240384007-A1 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION NOVARTIS AG (CH) 2024-11-21 — — US claimed
US-20200371091-A1 BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND USES THEREOF NOVARTIS AG (CH) 2020-11-26 — — US claimed
US-20200339704-A1 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION NOVARTIS AG (CH) 2020-10-29 — — US claimed
EP-3717907-A1 BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND USES THEREOF Novartis AG (CH) 2020-10-07 — — EP claimed
CN-111727373-A Chimeric antigen receptor targeting BCMA and uses thereof 诺华股份有限公司 2020-09-29 — — CN claimed
CN-111629749-A Compositions and methods for selective protein degradation 诺华股份有限公司 2020-09-04 — — CN claimed
EP-3697436-A1 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION Novartis AG (CH) 2020-08-26 — — EP claimed
WO-2019079569-A1 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION NOVARTIS AG (CH) 2019-04-25 — — WO claimed
US-12624118-B2 Trispecific binding molecules against BCMA and uses thereof NOVARTIS AG (CH) 2026-05-12 — — US disclosed
US-20260035473-A1 BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view NOVARTIS AG (CH) 2026-02-05 — — US disclosed
US-20250223359-A1 CD19 BINDING MOLECULES AND USES THEREOF NOVARTIS AG (CH) 2025-07-10 — — US disclosed
US-12275795-B2 Binding molecules against BCMA and uses thereof NOVARTIS AG (CH) 2025-04-15 — — US disclosed
US-12221481-B2 CD19 binding molecules and uses thereof NOVARTIS AG (CH) 2025-02-11 — — US disclosed
US-20240384007-A1 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION NOVARTIS AG (CH) 2024-11-21 — — US disclosed
EP-2749559-A1 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2014-07-02 — — EP disclosed
EP-2749559-A1 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2014-07-02 — — EP disclosed
WO-2009145899-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2009-12-03 — — WO disclosed
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2009-06-04 — — US disclosed
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2009-06-04 — — US disclosed
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2009-06-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339704-A1 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION CRBN, RPS27A, COPB1 CRBN 1/4885GSPT1 991/4885DDB1 390/4885
US-12221481-B2 CD19 binding molecules and uses thereof CD22, BCL9, CD2 CRBN 439/4885GSPT1 1039/4885DDB1 507/4885
US-20200371091-A1 BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND USES THEREOF BCR, CD47, TNFRSF9 CRBN 289/4885GSPT1 1867/4885DDB1 2058/4885
US-20240384007-A1 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION CRBN, RPS27A, COPB1 CRBN 1/4885GSPT1 991/4885DDB1 390/4885
US-20260035473-A1 BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view BCL9, BRCA1, VCAM1 CRBN 839/4885GSPT1 3145/4885DDB1 1379/4885
US-12624118-B2 Trispecific binding molecules against BCMA and uses thereof CD2, CD40, CD22 CRBN 239/4885GSPT1 2263/4885DDB1 172/4885
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 CRBN 4610/4885GSPT1 1959/4885DDB1 3649/4885
US-20250223359-A1 CD19 BINDING MOLECULES AND USES THEREOF CD22, BCL9, CD2 CRBN 425/4885GSPT1 978/4885DDB1 462/4885
US-12275795-B2 Binding molecules against BCMA and uses thereof EPCAM, CD40, BCR CRBN 1323/4885GSPT1 1504/4885DDB1 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.